Treatment with trastuzumab (Herceptin) boosts risk of heart failure or cardiomyopathy in breast cancer survivors, an observational study affirmed.
Women who received trastuzumab alone were 4.12 times more likely (95% CI 2.30 to 7.42) to go into heart failure after accounting for other factors, Erin Aiello Bowles, MPH, of the Group Health Research Institute in Seattle, and colleagues found.
Read the full story: http://bit.ly/RwF5RE
Source: MedPage Today
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
Dr Kathryn Lindley on Pregnancy-Related Cardiovascular Care Gaps and Training Initiatives
December 8th 2023Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.
Read More
Real-World Data Show Poor Outcomes Among Patients With ACS and Blood Cancers
December 8th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More